Dive Deep into Success: Ace the 2025 Certified Hyperbaric Technologist Exam!

Treating a healthy, pregnant patient with a carboxyhemoglobin (COHgb) level of 15% for carbon monoxide exposure is advisable due to several critical factors related to both maternal and fetal health. Carbon monoxide binds to hemoglobin more readily than oxygen, thereby reducing the oxygen-carrying capacity of blood. In pregnant patients, this is especially concerning, as it poses risks not only to the mother but also to the developing fetus, which relies on maternal blood for its oxygen supply.

At a COHgb level of 15%, the risk of hypoxia is significant. Pregnant women are generally more susceptible to the adverse effects of carbon monoxide due to physiological changes such as increased blood volume and alterations in blood gas concentrations. Additionally, elevated levels of carboxyhemoglobin can lead to fetal hypoxia, which may result in neurological damage or developmental issues.

The proactive approach in treating carbon monoxide exposure, especially at the threshold of 15% COHgb, is crucial in preventing these potential complications. Therefore, it is appropriate to initiate treatment regardless of the presence of symptoms, as some patients may not exhibit immediate signs of carbon monoxide poisoning, yet they can still be at risk.